NLK
MOLECULAR TARGETnemo like kinase
NLK (nemo like kinase) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NLK
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | sb 203580 | 4.92 | 136 |
| 3 | foretinib | 4.34 | 76 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | doramapimod | 4.06 | 57 |
| 6 | pazopanib | 3.69 | 39 |
| 7 | sb 202190 | 3.64 | 37 |
| 8 | lestaurtinib | 3.04 | 20 |
| 9 | gsk 690693 | 2.64 | 13 |
| 10 | ast 487 | 2.56 | 12 |
| 11 | tak 285 | 2.40 | 10 |
| 12 | encorafenib | 2.20 | 8 |
| 13 | osi 027 | 2.08 | 7 |
| 14 | Sorafenib | 1.61 | 4 |
| 15 | Dasatinib | 0.69 | 1 |
About NLK as a Drug Target
NLK (nemo like kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented NLK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NLK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.